10 reasons why you should use lisinopril Review article
Article Sidebar
Published:
Dec 31, 2016
Keywords:
ACE inhibitors, lisinopril, hypertension
Main Article Content
Abstract
Angiotensin converting enzyme inhibitors – ACE-I is one of the most popular class of drugs useful for the cardiovascular diseases treatment. Lisinopril which is the main representative of this group is well-tested. It has a lot of unique features which found it useful in clinical practice. In Poland lisinopril has indications in treatment of high blood pressure (in monotherapy and polypharmacotherapy), heart failure, and heart attacks during first 24 hours. However, new clinical trials show that lisinopril has bigger potential then we thought and in the nearest future we probably spread its indications.
Article Details
How to Cite
Dąbrowska, D., & Mamcarz , A. (2016). 10 reasons why you should use lisinopril. Medycyna Faktow (J EBM), 9(4(33), 307-312. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2203
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Januszewicz A., Januszewicz W., Rużyłło W.: Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Medycyna Praktyczna, Kraków 2009.
2. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśn. Tętn. 2011; 15: 55-82.
3. Terpstra W.F., May J.F., Smit A.J. et al.: Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J. Hypertens. 2004; 22: 1309-1316.
4. Malacco E., Santonastaso M., Vari N.A. et al.; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study: Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin. Ther. 2004; 26: 855-865.
5. Lancaster S.G., Todd P.A.: Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646-669.
6. Poldermans D., Glazes R., Kargiannis S. et al.: Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin. Ther. 2007; 29: 279-289.
7. Mancia G., Zanchetti A., Agabiti-Rosei E. et al.: Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95: 1464-1470.
8. Farsang C.; HAMLET Trial Investigation: Advantages of lisinopril amlodipine fixed combination therapy in hypertension. A comparative study of the efficacy and tolerability of amlodipine 5 mg and lisinopril 10 mg administered separately and in combination in hypertension. Hypertonia es Nephrologia 2004; 8: 72-78.
9. Farsang C., Abraham G., Kovacs P. et al.: The effectivity and safety of Amlodipin-Lisinopril Fix-combination in patients with ESSential hypertension (ALFESS Study). Hypertonia es Nefrologia 2009; 13: 81-87.
10. Mancia G., Grassi G.: Antihypertensive effects of combined lisinopril and hydrochlorothiazide in elderly patients with systodiastolic or systolic hypertension: results of a multicenter trial. J. Cardiovasc. Pharmacol. 1997; 30: 548-553.
11. Zuanetti G., Latini R., Maggioni A.P. et al.: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96: 4239-4245.
12. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Efect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
13. Cushman W.C., Davis B.R., Pressel S.R. et al.: Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J. Clin. Hypertens. (Greenwich) 2012; 14: 20-31.
14. Barzilay J.I., Davis B.R., Cutler J.A. et al.: Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 2006; 166(20): 2191-2201.
15. Potter J.F., Robinson T.G., Ford G.A. et al.: Controlling Hypertension, and hypotension immediately post-stroke (CHHIPS): a randomised, placebo- controlled, double-blind pilot trial. Lancet Neurology 2009; 8: 48-56.
16. Massie B.M., Armstrong P.W., Cleland J.G. et al.: Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. Assessment of Treatment with Lisinopril and Survival. Arch. Intern. Med. 2001; 161: 165-171.
17. Boden W.E., O’Rourke R.A., Teo K.K. et al.: Optimal medical therapy with or without PCI for stable coronary disease. New. Engl. J. Med. 2007; 356: 1503-1516.
18. Mogensen C.E., Neldam S., Tikkanen I. et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
19. Menne J., Farsang C., Deák L. et al.: Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J. Hypertens. 2008; 26: 1860-1867.
20. Goadsby P.J., Sprenger T.: Aktualne postępowanie i kierunki na przyszłość w profilaktyce i leczeniu doraźnym napadów migreny (tłum. z j. ang.). Neur. Prakt. 2011; 11(4): 47-64.
21. Solfrizzi V., Scafato E., Frisardi V et al.: Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age 2013; 35: 441-453.
22. Ponikowski P., Voors A.A., Anker S.D. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016; 37: 2129-2200.
2. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśn. Tętn. 2011; 15: 55-82.
3. Terpstra W.F., May J.F., Smit A.J. et al.: Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J. Hypertens. 2004; 22: 1309-1316.
4. Malacco E., Santonastaso M., Vari N.A. et al.; Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study: Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin. Ther. 2004; 26: 855-865.
5. Lancaster S.G., Todd P.A.: Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646-669.
6. Poldermans D., Glazes R., Kargiannis S. et al.: Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin. Ther. 2007; 29: 279-289.
7. Mancia G., Zanchetti A., Agabiti-Rosei E. et al.: Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997; 95: 1464-1470.
8. Farsang C.; HAMLET Trial Investigation: Advantages of lisinopril amlodipine fixed combination therapy in hypertension. A comparative study of the efficacy and tolerability of amlodipine 5 mg and lisinopril 10 mg administered separately and in combination in hypertension. Hypertonia es Nephrologia 2004; 8: 72-78.
9. Farsang C., Abraham G., Kovacs P. et al.: The effectivity and safety of Amlodipin-Lisinopril Fix-combination in patients with ESSential hypertension (ALFESS Study). Hypertonia es Nefrologia 2009; 13: 81-87.
10. Mancia G., Grassi G.: Antihypertensive effects of combined lisinopril and hydrochlorothiazide in elderly patients with systodiastolic or systolic hypertension: results of a multicenter trial. J. Cardiovasc. Pharmacol. 1997; 30: 548-553.
11. Zuanetti G., Latini R., Maggioni A.P. et al.: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96: 4239-4245.
12. Chaturvedi N., Sjolie A.K., Stephenson J.M. et al.: Efect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
13. Cushman W.C., Davis B.R., Pressel S.R. et al.: Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J. Clin. Hypertens. (Greenwich) 2012; 14: 20-31.
14. Barzilay J.I., Davis B.R., Cutler J.A. et al.: Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 2006; 166(20): 2191-2201.
15. Potter J.F., Robinson T.G., Ford G.A. et al.: Controlling Hypertension, and hypotension immediately post-stroke (CHHIPS): a randomised, placebo- controlled, double-blind pilot trial. Lancet Neurology 2009; 8: 48-56.
16. Massie B.M., Armstrong P.W., Cleland J.G. et al.: Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. Assessment of Treatment with Lisinopril and Survival. Arch. Intern. Med. 2001; 161: 165-171.
17. Boden W.E., O’Rourke R.A., Teo K.K. et al.: Optimal medical therapy with or without PCI for stable coronary disease. New. Engl. J. Med. 2007; 356: 1503-1516.
18. Mogensen C.E., Neldam S., Tikkanen I. et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
19. Menne J., Farsang C., Deák L. et al.: Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J. Hypertens. 2008; 26: 1860-1867.
20. Goadsby P.J., Sprenger T.: Aktualne postępowanie i kierunki na przyszłość w profilaktyce i leczeniu doraźnym napadów migreny (tłum. z j. ang.). Neur. Prakt. 2011; 11(4): 47-64.
21. Solfrizzi V., Scafato E., Frisardi V et al.: Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age 2013; 35: 441-453.
22. Ponikowski P., Voors A.A., Anker S.D. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016; 37: 2129-2200.